Stocks had another mixed day, despite some key winners and losers. China's surprise rate hike came amid word of a rate by the European Central Bank, expected on Thursday of this week. Brent Crude hit what appears to be a two-year high and even Ben Bernanke's remarks on inflation didn't add much to the mix. That being said, it was not known until the final minute if the markets were going to be in the red or the black for the trading day.

Here were today's unofficial closing bell levels:

Dow Jones: 12,393.90 -6.13 (-0.05%)

S&P500: 1,332,63 -0.24 (-0.02%)

Nasdaq: 2,791,19 +2.00 (0.07%)

Top Analyst Upgrades & Downgrades

It should surprise no one that oil stocks have taken the lead in the first quarter, while financial stocks -- after a good two-year run -- have been tamed. This is how things have shaped up through the first quarter for my 2011 stock picks. (For a look at my original picks, see here: part 1, part 2, and part 3.)

Normally, if I said a business was underwater, investors would think the worst. Actually, in the summer Noble Corp (NE) was underwater -- and investors were not impressed. However, this was a great buying opportunity, and although the company is still underwater, it is also a market leader among my stock picks and the overall market -- even among oil industry players. With its fleet of 69 offshore drilling rigs, Noble stands tall.

Analyst Upgrades

• Aetna (AET) to buy from neutral at Goldman.
• Kellogg (K) to buy from neutral at UBS.
• PetSmart (PETM) to outperform from market perform at JMP Securities.
• NetApp (NTAP) and Scripps Networks (SNI) to buy from hold at Wunderlich.
• Thoratec (THOR) to buy from hold at Auriga.
• ArcelorMittal (MT) to overweight from neutral at HSBC.
• Bristol-Myers (BMY) to outperform from neutral at Cowen.
• Eaton Vance (EV) to neutral from sell at Ticonderoga.
• Adtran (ADTN) to buy from underperform at BofA/Merrill.

Much of the U.S. was buried in ice-cold weather. Jobless claims improved to levels better than expected, earnings kept coming out, and inflation is slightly higher, as the FOMC wants to see. Ben Bernanke said that things are progressing as expected in quantitative easing and did not exactly signal another round of QE3. Strong retail sales may have carried the day.

Here were today's unofficial closing bell levels ahead of Friday's non-farm payrolls and unemployment data:

Dow Jones: 12,062.26 +20.29 (0.17%)
S&P 500: 1,307.10 +3.07 (0.24%)
Nasdaq: 2,753.88 +4.32 (0.16%)

Top Analyst Upgrades & Downgrades

U.S. stock futures are mixed this morning, as investors await jobless-claims data and earnings report from Merck (MRK). Futures on the Dow Jones Industrial Average rose 7 points to 11,992 and S&P 500 futures fell 0.40 point to 1,299.60. Nasdaq 100 futures fell 3.50 to 2,316.25.

The Dow index gained 1.81 points or 0.02% to close at 12,042 yesterday.

Data on weekly jobless claims and fourth quarter productivity will be released at 8:30 a.m. ET. The ISM report on service sector activity in January and factory orders for December will both be released at 10 a.m. ET.

US retailers such as Wal-Mart Stores (WMT) are scheduled to report same-store sales for January.

Oil Services Holders Trust (OIH) closed above $155 as crude oil futures traded above $91 according to Bloomberg. February and April put option implied volatility of 30 is near its 26-week average of 30 according to Track Data, suggesting non-directional price movement.

Merck & Co., Inc. (MRK) overall option implied volatility is at 21 according to Track Data, below its 26-week average of 23 into its release of Q4 EPS on February 3, suggesting decreasing price movement.

Options Update is by Stock Specialist Paul Foster of theflyonthewall.com

We are only one month into the new year and there have not been many dull moments. Games are going on in the Middle East and they are not the friendly kind. In Egypt a million plus protesters are playing a game of chicken with the Mubarak government demanding he step down from his 32-year-old reign as perpetual president.

This is not radical Islam fundamentalists; it is even more fundamental. The people want to improve their daily lives in a meaningful way. Education, infrastructure, clean water and clean streets. Speaking of infrastructure and getting back to the less dramatic but still important great stock picks Telefonica (TEF) and General Electric (GE) were the big winners so far bouncing over 10% in January.

Analyst Upgrades

• Large Cap Pharmaceuticals sector upgraded to Overweight at Wells Fargo.
• Archer Daniels (ADM) upgraded to Outperform from Neutral at Credit Suisse.
• Cypress Semi (CY) upgraded to Buy from Neutral at UBS.
• MFA Financial (MFA) upgraded to Buy from Hold at Jefferies.
• Blackstone (BX) upgraded to Buy from Hold at Jefferies.
• Comerica (CMA) upgraded to Hold from Sell at Citigroup.
• Dollar Tree (DLTR) upgraded to Overweight from Equal Weight at Morgan Stanley.
• NuVasive (NUVA) upgraded to Outperform from Market Perform at Leerink.
• Cogdell Spencer (CSA) upgraded to Buy from Hold at Jefferies.
• Hersha Hospitality (HT) upgraded to Hold from Underperform at Jefferies.
• G&K Services (GKSR) upgraded to Outperform from Neutral at RW Baird.
• Graham Packaging (GRM) upgraded to Buy from Neutral at Goldman.
• Shaw (SJR) upgraded to Neutral from Underperform at BofA/Merrill.

Thursday saw seasonality make for a weak jobs report, some manufacturing data came in lower than expected and the rate of wholesale inflation looks to be perking up if you include food and energy. A surprise rate hike from South Korea also took the headlines away from the E.U. and U.K. central banks keeping rates unchanged. Even Ben Bernanke being more confident and calling for 3% to 4% GDP growth in 2011 failed to bring new buyers. The DJIA was weaker than most indexes up until the end of the today.

Here are Thursday's unofficial closing bell levels:

Dow Jones 11,731.90 -23.54 (-0.20%)
S&P 500 1,283.76 -2.20 (-0.17%)
Nasdaq 2,735.29 -2.04 (-0.07%)

Top Analyst Upgrades & Downgrades

Merck (MRK - option chain) stock is trading lower today after the company said it has ended a clinical study for its cardiovascular drug Vorapaxar in patients with acute coronary syndrome. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on MRK.

This morning, MRK opened at $35.59. So far today the stock has hit a high of $35.78 and a low of $34.55. As of 12:15, MRK is trading at $34.63, down $2.52 (-6.8%). The chart for MRK looks bullish and S&P gives MRK a positive 4 STARS (out of 5) buy ranking.

I have already gone on record this year saying that financial companies and insurance stocks are going to continue to rebound. In my previous two posts Chasing Value: 2011 Stock Picks -- 5 of 11 and Chasing Value: 2011 Stock Picks -- 6, 7, 8, 9, I included several financial institutions. Today I add an insurance company.

The industry got whacked hard for many reasons. For one, it makes a significant amount of profit by investing its float, and like every other investor, the industry lost a pile of money in the financial crisis. It was embroiled more directly than some industries, as several insurers are affiliated with banks. Finally the housing crisis meant disruption to payment streams by homeowners who were delinquent on more than their mortgages.

Analyst Upgrades

• Research In Motion (RIMM) to buy from hold at Jefferies.
• Citigroup (C) to buy from hold at ISI Group.
• Integrated Silicon (ISSI) to buy from hold at Auriga.
• Kinross Gold (KGC) to outperform from neutral at Credit Suisse.

Merck (MRK - option chain) shares are rising today after the company said a study of its experimental cholesterol drug Anacetrapib showed the drug dramatically lowered bad cholesterol (LDL) while raising so-called good cholesterol (HDL). If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on MRK.

MRK opened this morning at $34.81. So far today the stock has hit a low of $34.52 and a high of $34.94. As of 12:05, MRK is trading at $34.65 up 0.55 (1.6%). The chart for MRK looks bullish and S&P gives MRK a positive 4 STARS (out of 5) buy ranking.

Today is election day. Currently, intrade.com is projecting a 97% chance that the Republicans will take control of the House of Representatives and a 48% chance that they will win the Senate. What could a landslide win for the Republican Party mean for the stock market?

Some observers are suggesting that gridlock in Washington, along with a more business friendly atmosphere, could be a catalyst for stock prices to rise. This, however, is offset by concerns about cuts in government spending. The private economy is sputtering, and near-term spending cuts could have a detrimental effect on the recovery. Therefore, instead of focusing on the broader market, investors may want to look at some specific sectors that may benefit from a Republican victory.

Three interesting areas are oil services, financials, and healthcare. The thinking is that some of the regulatory headwinds facing these sectors may be lifted if the political atmosphere in Washington D.C. changes. Some observers believe that a Republican-led House of Representatives will be able to chip away at some of the Obamacare legislation. This should benefit large pharmaceutical companies such as Merck (MRK) and Pfizer (PFE).

There are lots of analysts out there who say that, over the long term, stocks in the pharmaceutical sector should do well. For the most part, they are talking about cash rich pharmaceutical companies such as Pfizer (PFE), McKesson (MCK), Medtronic (MDT) and Forest Laboratories (FRX) according to Gene Marcial of our sister site, DailyFinance.

But there are other, less obvious ways, to play growth in the pharmaceutical industry as well. Hilary Kramer, editor of GameChangerStocks.com, recently recommended two stocks that are "under the radar" and could do very well in the near future.